Chronic Pain Clinical Trials Epilepsy Media 
Cannabis Law Report
DECEMBER 20, 2021
(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Media: Laura Radocaj. For more information, please visit www.virpaxpharma.com. Chipman, CPA.
Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Media: media@mymd.com. in the blood. 646) 421-9523.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 8, 2021
Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.
Cannabis Law Report
OCTOBER 5, 2021
The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. Media: media@mymd.com. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. Investor: Robert Schatz. 646) 421-9523.
Cannabis Law Report
AUGUST 21, 2019
The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. The final guideline is expected to be published in November 2019.
Cannabis Law Report
SEPTEMBER 22, 2021
Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Media Contact: media@mymd.com. 646) 421-9523.
MMJ Recs
DECEMBER 22, 2023
Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders. One significant factor is the recognition of the opioid crisis and the need for alternative pain management strategies.
Expert insights. Personalized for you.
52 
Let's personalize your content